Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Two-Drug combo finally beat chronic hepatitis b?

NCT ID NCT04749368

Completed ⭐️ CURE ⭐️ Sponsor: Brii Biosciences Limited Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether a combination of two experimental drugs, BRII-835 and BRII-179, can clear the hepatitis B virus from the body in adults with chronic infection. Participants will receive the drug combination and then be monitored to see if they can safely stop their standard antiviral therapy. The goal is to achieve a sustained loss of hepatitis B surface antigen, a key marker of infection, which could point toward a functional cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of two experimental drugs: BRII-835 (VIR-2218) and BRII-179 (VBI-2601)
What this could lead to
If successful, this combination could offer a functional cure for chronic hepatitis B, allowing patients to stop long-term antiviral treatment.
What could go wrong
This is an early-phase trial with a small number of participants. The drugs may not achieve sustained virus clearance, and side effects or safety issues could emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B, CHRONIC

Contacts and locations

Locations

  • Investigative Site 61001

    Westmead, New South Wales, 2145, Australia

  • Investigative Site 61002

    Kingswood, New South Wales, 2747, Australia

  • Investigative Site 61004

    Herston, Queensland, 4029, Australia

  • Investigative Site 64001

    Auckland, 2025, New Zealand

  • Investigative Site 64002

    Dunedin Central, Dunedin, 9016, New Zealand

  • Investigative Site 65001

    Singapore, 169608, Singapore

  • Investigative Site 65002

    Singapore, 529889, Singapore

  • Investigative Site 66001

    Bangkok, 10330, Thailand

  • Investigative Site 66002

    Khon Kaen, 40002, Thailand

  • Investigative Site 66003

    Chiang Mai, 50200, Thailand

  • Investigative Site 66004

    Pathum Thani, 12120, Thailand

  • Investigative Site 66005

    Nonthaburi, 11000, Thailand

  • Investigative Site 66006

    Nonthaburi, 11000, Thailand

  • Investigative Site 66007

    Songkhla, 90110, Thailand

  • Investigative Site 82001

    Seoul, 3080, South Korea

  • Investigative Site 82002

    Seoul, 5505, South Korea

  • Investigative Site 82003

    Seongnam-si, Gyeonggi-do, 13496, South Korea

  • Investigative Site 82004

    Busan, 49241, South Korea

  • Investigative Site 82005

    Seoul, 3722, South Korea

  • Investigative Site 85201

    Hong Kong, China

  • Investigative Site 85202

    Hong Kong, China

  • Investigative Site 85203

    Hong Kong, China

  • Investigative Site 85204

    NEW Territories, Hong Kong, China

  • Investigative Site 88601

    Kaohsiung, Taiwan, 83301, China

  • Investigative Site 88602

    Changhua, Taiwan, 500, China

  • Investigative Site 88603

    Taichung, Taiwan, 40447, China

  • Investigative Site 88604

    Kaohsiung, Taiwan, China

  • Investigative Site 88605

    Taipei CITY, 10048, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.